Share class: Tokai Pharmaceuticals Inc

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A0110,08600 99.96 %
Stock B159,739,27559,713,501 ( 99.96 %) 0
Stock C04,42200

Major shareholders: Tokai Pharmaceuticals Inc

NameEquities%Valuation
BVF, Inc.
10.53 %
6,293,282 10.53 % 26 M $
BVF Partners LP
10.41 %
6,215,942 10.41 % 26 M $
RA Capital Management LP
5.97 %
3,566,338 5.97 % 15 M $
Frazier Management LLC
4.449 %
2,657,699 4.449 % 11 M $
Armistice Capital LLC
3.957 %
2,364,000 3.957 % 10 M $
Vanguard Global Advisers LLC
2.621 %
1,565,487 2.621 % 6 M $
Schonfeld Strategic Advisors LLC
2.511 %
1,500,000 2.511 % 6 M $
Zimmer Partners LP
2.402 %
1,434,727 2.402 % 6 M $
Sphera Funds Management Ltd.
2.172 %
1,297,321 2.172 % 5 M $
Woodline Partners LP
1.411 %
842,892 1.411 % 3 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
NameEquities%Valuation
BVF Partners LP
71.24 %
4,420 71.24 % 18 210 $
NameEquities%Valuation
BVF Partners LP
29.54 %
100,182 29.54 % 412 750 $

Breakdown by shareholder type

Institutional41.31%
Other10.66%
State Street Corp.0.27%
Individuals0.04%
Unknown47.72%

Based on 1000 largest holdings

Geographical origin of shareholders

United States 49.99%
Israel 2.17%
Canada 0.08%
Individuals 0.04%

Based on 1000 largest holdings

Logo Tokai Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Employees
-
More about the company